Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
FASTEST-TB
Tuberculosis
Framework programme: 6
Call: 3
Project number: LSHP-CT-2005-037912
EC contribution: € 1,217,800
Duration: 36 Months
Type: STREP
Starting date: 1 December 2006
Graphic element Development and Clinical Evaluation of Fast Tests for Tuberculosis Diagnosis
Keywords: Tuberculosis, TB diagnosis, Serology, Antigen discovery, TB-Fast Test Development, Clinical Evaluation

Summary:

It is widely accepted that rapid, cost-effective diagnosis of high sensitivity and specificity is a prerequisite for the prevention and control of tuberculosis (TB); a global disease in humans, killing more than 3 million people annually. Methods and devices currently in use do not meet these requirements.

New strategies are urgently needed for combating the problems of TB diagnosis. First-generation detection tests using a novel, high-speed device for quantitative measurement of antigens in sputum and urine of TB patients have recently been developed. The device also enables simultaneous measurement of antigens and antibodies within 20 minutes. The main objectives of this proposal are to:

  1. Identify novel antigens using genomic and proteomic approaches
  2. Purify sufficient quantities of antigens and raise antibodies
  3. Optimise immobilisation conditions for the specific antigens
  4. and antibodies on different Carriers
  5. Manufacture and evaluate different, fast tests using approximately 6 000 clinical specimens (sputum, saliva, serum, urine) from TB patients at study sites in Asia, Africa, America and Europe.

Such tests and devices would be a major breakthrough in the early diagnosis and prevention of tuberculosis. The Coordinator (LIONEX, an SME) in cooperation with a WHO centre, a lung hospital in Germany and additional expert scientists from low-resource, TB-endemic countries (India, Turkey, Nigeria, Mexico) shall in this project, evaluate the clinical potential of antigen and antibody detection using the high speed, cost-effective Point of Care (POC) tests, with which results can be obtained on site within 20 minutes. Finally, the project also aims at developing TB-HIV dual antibody detection POC Fast tests.

The outcome of this project will lead to new inexpensive and fast diagnostic tests that can be performed on site without the requirement of any complicated or expensive instruments. The tests will provide results within 15-20 minutes and shall be preferably non-invasive.

Background:

The current methods of diagnosis (microscopy, culture, chest x-ray, PPD, PCR) are inadequate for the diagnosis of tuberculosis, as these are either too slow, not sensitive enough or too expensive. The usual means of diagnosing TB in the majority of developing countries where culture facilities are not available is by the detection of acid fast bacteria in sputum by direct microscopy. But this test is laborious and insensitive as only 40-60% of all adults with pulmonary TB can be identified by the current smear test using Ziehl-Neelsen staining. In low-resource TB endemic countries, poor access to high-quality microscopy services and/ or paucibacillary nature of pulmonary TB in HIV positive patients results in even lower rates of sensitivity of AFB (acid fast bacilli) detection. Thus, the two main problems concerning TB diagnosis are:

  1. Sputum microscopy, currently the most widely used method
  2. to detect tuberculosis is cumbersome and insensitive, leaving many patients undetected and
  3. Bacterial culture, the gold standard, is more sensitive, but takes 4-6 weeks to complete, and is too complex for most settings where TB is endemic.
    The HIV pandemic has led to a resurgence of TB as a major public health problem. Immunodeficient HIV-positive patients are particularly vulnerable to TB and are even more difficult to diagnose than those who are diagnosed HIV negative.

Aim:

To develop and evaluate high-speed, POC tests based on the detection of antibodies and antigens in body fluids, e.g. whole-blood, serum, urine, sputumor saliva for the diagnosis of both pulmonary and extra-pulmonary TB.

Expected results:

The outcome of this project will lead to new inexpensive and fast diagnostic tests that can be performed on site without the requirement of any complicated or expensive instruments. The tests will provide results within 15-20 minutes and shall be preferably non-invasive.

Potential applications:

Potential applications of this project results are:

  • The new Fast tests shall enable accurate TB diagnosis on the spot within 15-20 minutes
  • Inexpensive TB diagnosis shall be feasible in low-resource settings highly suitable to TB endemic countries
  • IAntigen detection Fast tests will have considerable advantages over current methods especially when dealing with HIV positive populations, which show reduced immune response
  • Additional significant advancement shall be made by developing dual HIV-TB tests which are urgently needed in endemic countries in Africa and Asia where HIV infection is increasing daily.

Coordinator:

Dr. Mahavir SINGH
CEO - LIONEX Diagnostics & Therapeutics GmbH,
Mascheroder Weg 1 b
38124 Braunschweig
Germany
Tel: +49-531-2601266 / Mobile: 0175 594 22 91
Fax: +49-531-260 11 59
E-mail: info@lionex.de
website: www.lionex.de

Partners:

Principal
Scientific
Participants
Official Address Other Information
2 Françoise PORTALES Institute of Tropical Medicine
Nationalestraat 155 Antwerp
Belgium
Tel: 0032-247-6317
Fax: 0032-247-6333
E-mail: portaels@itg.be, kjanssens@itg.be
Website: www.itg.be
3 Helmut BLOECKER Department of Genome Analysis
GBF, Mascheroder Weg 1, D-38124
Braunschweig
Germany
Tel: 0049 531 6181 220
Fax: 0049 531 6181 292
E-mail: bloecker@gbf.de
Website: http://www.genome.gbf.de
4 Harald HOFFMANN Institute of Microbiology and Laboratory
Medicine.WHO-reference laboratory for
Tuberculosis and Mycobacteria.,
Robert-Koch-Allee 2
D-82131 München-Gauting
Germany
Tel +49 89 85791 8234
Fax +49 89 85791 8235
E-mail: harald.hoffmann@asklepios.com
Website: http://www.asklepios.com/Gauting
5 Olcay YEGIN Akdeniz University Medical School
Department of Pediatric Immunology
Antalya 07050
Turkey
Tel 00902422274343 (66223)
Fax: 00902422274444
E-mail: yegin@akdeniz.edu.tr
http://www.akdeniz.edu.tr
6 PR NARAYAN / Dr. Alamelu RAJA Tuberculosis Research Centre, India
Mayor V. R. Ramanathan Road,
Chetput CHENNAI - 600 031
INDIA
Telephone:+91 (044) 2836 9626
FAX:+91 (044) 2836 2528
E-mail: alameluraja@yahoo.com,
alameluraja @gmail.com
Website: www.trc-chennai.org
7 Gertrud BIERSACK Sacred Heart Hospital, Oswald Madecki
Road, Lantoro, Abeokuta, 110001
Ogun State
Nigeria
Tel: 00234-(0)39-240415
Fax: 00234-(0)39-245051
Email: shh@linkserve.com
Website: www.geocities.com/sacredheartabeokuta
8 Jürgen Knobloch Institut für Tropenmedizin
Universitätsklinikum Tübingen
Keplerstr 15, D-72074 Tübingen
Germany
Tel: 0049-7071-2986022
Fax: 0049-7071-295267
Email: jnknoblo@med.uni-tuebingen.de
Website: www.med.uni-tuebingen.de/tropenmedizin/index.html
9 Iris ESTRADA Dept. of Immunology. National School
of Biological Sciences. Prol. Carpio
y Plan de Ayala s/n. Santo Tomas.
México, D.F. MEXICO. CP 11340
México, D.F. MEXICO. CP 11340
Tel: 00 5255-57296300 ext 62369
Fax: 0052-55-53 9635 03
Email: iestrada@encb.ipn.mx

 
 
top
Graphic element